- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 10.03. | Sandoz to set up standalone biosimilars unit as it eyes upcoming 'golden decade' of patent losses | ||
| 10.03. | AbbVie's Robert Michael earns hefty pay bump to $32.5M in 2nd year as CEO | ||
| 10.03. | Patients want price transparency, e-commerce experience from pharma DTP platforms: survey | ||
| 10.03. | Novo Nordisk's US headquarters under fire in latest FDA warning letter | ||
| 10.03. | Leerink questions whether BioNTech can thrive without their 'founders' insight' as stock drops | ||
| 10.03. | Filana leaves Cassava Sciences roots behind amid branch into epilepsy | ||
| 10.03. | CSL telegraphs 300 new hires as it breaks ground on $1.5B plasma-based medicine plant near Chicago | ||
| 10.03. | FDA approves leucovorin for ultrarare cerebral folate deficiency subset without clinical trial | ||
| 09.03. | FDA unveils 4th revision of draft guidance for looser biosimilar testing requirements | ||
| 09.03. | Lilly rewards CEO David Ricks with $36.7M pay package for 2025, fueled by GLP-1 success | ||
| 09.03. | Spruce hooks a commercial chief to prep for rare disease launch | ||
| 09.03. | Novo and Hims make nice, striking deal to sell Ozempic, Wegovy on Hims' telehealth platform | ||
| 09.03. | Sotyktu take 2: BMS' first-in-class pill gains FDA nod to treat psoriatic arthritis | ||
| 09.03. | 'SNL' pokes fun at mysteries of Amgen's Otezla for plaque psoriasis | ||
| 09.03. | Novo's troubled Indiana plant claims another victim as FDA rejects Incyte's lung cancer application | ||
| 09.03. | Ipsen backs away from cancer med Tazverik after safety signals emerge in lymphoma trial | ||
| 06.03. | Lonza hands off capsule business to investment firm Lone Star in $3B deal | ||
| 06.03. | Democrats press 11 pharmas for 'any evidence' their Trump pricing deals deliver savings for Medicaid | ||
| 06.03. | Sanofi strikes deal with Brazil's EMS to sell generics manufacturer Medley | ||
| 06.03. | Super Bowl, Winter Olympics defined TV drug ad spending in February, led by AbbVie's Rinvoq | ||
| 06.03. | Pfizer breaks into obesity market in China with approval for Sciwind-partnered GLP-1 | ||
| 06.03. | Taiwan earmarks $755M for multi-year drug supply resilience program | ||
| 06.03. | Servier to widen rare cancer offerings with $2.5B buyout of Day One and glioma drug Ojemda | ||
| 06.03. | Fierce Pharma Asia-Kyowa ends OX40 program; Sanofi licenses first-in-class drug; BioNTech advances Duality ADC | ||
| 05.03. | Forma Life Sciences launches with oral solid dose focus, joining class of new CDMOs |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.